Clinical Trials in Boston

Showing 8641-8660 of 17,836 trials

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

NCT02616055

Subjects who received tesevatinib in Study KD019-101 and completed 24 months of treatment will continue on the dose of tesevatinib they were receiving at 24 months on the KD019-101 study.

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Kadmon Corporation, LLC15 participantsStarted Dec 2015

Los Angeles, California, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +3 more locations

TERMINATEDPhase 3< 1 mile

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

NCT02999854

The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration of high dose cyclophosphamide (PTCy) in patients with a hematologic malignancy. An additional objective of the study is to compare the effect of the two treatments on quality of life.

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome

Kiadis Pharma63 participantsStarted Nov 2017

Duarte, California, United States • La Jolla, California, United States • Los Angeles, California, United States +39 more locations

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

Find Trials by Condition in Boston

Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

Memory Aid by Intranasal Insulin in Diabetes (MemAID)

Kidney Precision Medicine Project

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Struvite Stones Antibiotic Study

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

The BRIgHT Program: Building Resilience in HIV Together

Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

Gene Transfer Clinical Study in Crigler-Najjar Syndrome

Phenotypes, Biomarkers and Pathophysiology in Spastic Ataxias

Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI

A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

Objective Pain Measurement Using a Wearable Biosensor and a Mobile Platform in Patients With Endometriosis

First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome